A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)

A Randomized, Open-Label Clinical Study to Assess the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine When Administered Concomitantly With RotaTeq™ or Rotarix™ in Healthy Infants in South Africa

This study will evaluate the immunogenicity and safety of the pertussis component of DTwP (whole-cell pertussis containing vaccine) when administered concomitantly with RotaTeq™ or Rotatrix™.

Inclusion Criteria:

• Healthy infants

Exclusion Criteria:

• History of abdominal disorders, intestinal folding, or abdominal surgery
• Impaired immune system
• Prior administration of any rotavirus vaccine or DTwP/DTaP
• Fever of >= 38.1C (100.5F) at the time of vaccination
• History of prior rotavirus infection, chronic diarrhea, or failure to thrive
• Evidence of active gastrointestinal illness